Sanofi’s Covid vaccine is not for now. the French pharmaceutical giant is still awaiting the results of its latest clinical trial (phase 3), planned during the first quarter of 2022, to request a possible marketing authorization from the health authorities of the various countries.
Read also: Covid-19. New delay for the French Sanofi vaccine: will it ultimately be useful?
Doliprane, an ally of the Covid vaccine
The presentation this Friday, February 4, 2022 of its annual results nevertheless reveals that other Sanofi products have indirectly benefited from the Covid pandemic. If you have been vaccinated against the coronavirus, you have probably been prescribed Doliprane. However, the latter remains one of the star drugs in Sanofi’s “consumer health” activity (it is also manufactured for the most part for the whole world in Lisieux, in Calvados, and in Compiègne, in Oise), in the “Pain” category.
The trend is the same across Europe, as well as in other countries of the world, because Sanofi is largely present internationally (overall, it only generates 6% of its turnover in France). In 2021, sales of its pain relief products thus increased by 7.2% (at constant exchange rates), to reach 1.1 billion euros.
Boosted flu vaccination
Sanofi is also the world leader in sales of flu vaccine. The latter does not protect against the coronavirus, but combining the two infections could increase morbidity in frail people, many have therefore been vaccinated in the past two years. At the end of 2020 and the beginning of 2021, when no Covid vaccine was yet available and their delivery was done in dribs and drabs, other people also got vaccinated against the flu, thinking that it would thus stimulate their system. immune.
At the end of 2021, in France, the government and the High Authority for Health recommended to the most vulnerable French people to recall the Covid-19 vaccine and the seasonal flu vaccine at the same time. Other people less at risk have done the same. Consequence for Sanofi, “2021 was another record year for flu vaccines with sales up 5.9% to 2.6 billion euros”, he announces.
Read also : Flu. The largest vaccine producer in the world is in Normandy
Helping with Covid vaccines
Finally, in the absence of having marketed its own vaccine against Covid, Sanofi is using three of its factories to produce those of its competitors BioNTech / Pfizer, Moderna and Johnson & Johnson. 100 million doses were manufactured at the end of December 2021 by Sanofi, which does not specify how much it earned.
In 2021, Sanofi performed well overall, with a total turnover of nearly 37.8 billion euros (+4.8%), an operating margin for activities which rose to 28.4%, and net income of 8.2 billion euros, up 11.8%.
At the same time, Sanofi also intends to weigh more heavily in the fight against cancer, which kills 10 million people each year worldwide. As World Cancer Day is being held on February 4, he has joined forces with several national healthcare and research institutions – Gustave Roussy, Inserm, the Institut Polytechnique de Paris and the University of Paris-Saclay.
Their objective, presented on February 4 with the Ministers of Health Olivier Véran and Research Frédérique Vidal: to accelerate the realization of industrial projects and the provision of treatments through the development of diagnostics, drugs, devices and services, by making work all public and private actors in Villejuif, in an area of several hectares in the heart of Greater Paris.
–
